Profile of cholinomimetic drugs in primates : status of screens for potential Alzheimer therapiesRUPNIAK, N. M. J.Drug development research. 1992, Vol 27, Num 2, pp 77-88, issn 0272-4391Article

Therapeutic potential of tachykinin receptor antagonists in depression and anxiety disordersRUPNIAK, N. M. J.Handbook of experimental pharmacology. 2004, Vol 164, pp 341-357, issn 0171-2004, 17 p.Article

CHRONIC CLOZAPINE TREATMENT OF RATS DOWN-REGULATES CORTICAL 5-HT₂ RECEPTORSREYNOLDS GP; GARRETT NJ; RUPNIAK N et al.1983; EUROPEAN JOURNAL OF PHARMACOLOGY; ISSN 0014-2999; NLD; DA. 1983; VOL. 89; NO 3-4; PP. 325-326; BIBL. 5 REF.Article

Non-specific inhibition of dopamine receptor agonist-induced behaviour by the trachykinin NK₁ receptor antagonist CP-99,994 in guinea-pigsRUPNIAK, N. M. J; JACKSON, A.European journal of pharmacology. 1994, Vol 262, Num 1-2, pp 171-175, issn 0014-2999Article

Use of a grooming and foraging substrate to reduce cage stereotypies in macaquesLAM, K; RUPNIAK, N. M. J; IVERSEN, S. D et al.Journal of medical primatology. 1991, Vol 20, Num 3, pp 104-109, issn 0047-2565Article

Pharmacological characterization of spontaneous or drug-associated purposeless chewing movements in ratsRUPNIAK, N. M. J; JENNER, P; MARSDEN, C. D et al.Psychopharmacologia. 1985, Vol 85, Num 1, pp 71-79, issn 0033-3158Article

Enhancement of stereotypy induced by nomifensine in rats during continuous chronic haloperidol treatmentRUPNIAK, N. M. J; JENNER, P; MARSDEN, C. D et al.Neuroscience letters. 1984, Vol 50, Num 1-3, pp 63-65, issn 0304-3940Article

Inhibition of pentagastrin-induced pressor response in conscious rats by the CCK-B receptor antagonist CI-988 and chlordiazepoxideWEBB, J. K; RUPNIAK, N. M. J; BOYCE, S et al.Regulatory peptides. 1996, Vol 61, Num 1, pp 71-76, issn 0167-0115Article

Psychomotor activity and cognitivie disruption attributable to NMDA, but not sigma, interactions in primatesBOYCE, S; RUPNIAK, N. M. J; STEVENTON, M. J et al.Behavioural brain research. 1991, Vol 42, Num 2, pp 115-121, issn 0166-4328Article

Nigrostriatal damage is required for induction of dyskinesias by L-DOPA in squirrel monkeysBOYCE, S; RUPNIAK, N. M. J; STEVENTON, M. J et al.Clinical neuropharmacology. 1990, Vol 13, Num 5, pp 448-458, issn 0362-5664, 11 p.Article

A comparison of the effects of acute and one year's continuous neuroleptic treatment on the release of [³H] glutamate and [³H] acetylcholine from rat striatal slicesKERWIN, R. W; RUPNIAK, N. M. J; JENNER, P et al.Neuroscience. 1984, Vol 11, Num 1, pp 205-210, issn 0306-4522Article

Functional increase in striatal dopaminergic activity following continuous long-term treatment with trifluoroperazineKERWIN, R; RUPNIAK, N. M. J; JENNER, P et al.Neuroscience letters. 1984, Vol 45, Num 3, pp 329-334, issn 0304-3940Article

Changes in apomorphine-induced stereotopy as a result of subacute neuroleptic treatment correlates with increased D-2 receptors, but not with increases in D-1 receptorsFLEMINGER, S; RUPNIAK, N. M. J; HALL, M. D et al.Biochemical pharmacology. 1983, Vol 32, Num 19, pp 2921-2927, issn 0006-2952Article

Induction of cognitive impairment by scopolamine and noncholinergic agents in rhesus monkeysRUPNIAK, N. M. J; SAMSON, N. A; STEVENTON, M. J et al.Life sciences (1973). 1991, Vol 48, Num 9, pp 893-899, issn 0024-3205, 7 p.Article

NB-355: A novel prodrug for L-DOPA with reduced risk for peak-dose dyskinesias in MPTP-treated squirrel monkeysTYE, S. J; RUPNIAK, N. M. J; NARUSE, T et al.Clinical neuropharmacology. 1989, Vol 12, Num 5, pp 393-403, issn 0362-5664Article

Enantioselective inhibition of the formalin paw late phase by the NK₁ receptor antagonist L-733,060 in gerbilsRUPNIAK, N. M. J; CARLSON, E; BOYCE, S et al.Pain (Amsterdam). 1996, Vol 67, Num 1, pp 189-195, issn 0304-3959Article

Anxiolytic-like and antinociceptive effects of MK-801 accompanied by sedation and ataxia in primatesRUPNIAK, N. M. J; BOYCE, S; TYE, S et al.Pharmacology, biochemistry and behavior. 1993, Vol 44, Num 1, pp 153-156, issn 0091-3057Article

Interpretation of changes in apomorphine-induced stereotyped behaviour in rats receiving continuous administration of trifluoperazine for 15 monthsRUPNIAK, N. M. J; BOYCE, S; JENNER, P et al.Neuropharmacology. 1984, Vol 23, Num 8, pp 893-898, issn 0028-3908Article

Differential effects of D₁ and D₂ agonists in MPTP-treated primates: Functional implications for Parkinson's diseaseBOYCE, S; RUPNIAK, N. M. J; STEVENTON, M. J et al.Neurology. 2001, Vol 57, Num 10, pp S27-S33, issn 0028-3878, SUP3Article

Characterisation of dyskinesias induced by L-dopa in MPTP-treated squirrel monkeysBOYCE, S; RUPNIAK, N. M. J; STEVENTON, M. J et al.Psychopharmacology. 1990, Vol 102, Num 1, pp 21-27, issn 0142-8411, 7 p.Article

Intra-amygdala injection of the substance P (NK₁ receptor) antagonist L-760735 inhibits neonatal vocalisations in guinea-pigsBOYCE, S; SMITH, D; CARLSON, E et al.Neuropharmacology. 2001, Vol 41, Num 1, pp 130-137, issn 0028-3908Article

Onset and progression of motor deficits in motor neuron degeneration (mnd) mice are unaltered by the glycine/NMDA receptor antagonist L-701,324 or the MAO-B inhibitor R(-)-deprenylBOYCE, S; WEBB, J. K; CARLSON, E et al.Experimental neurology (Print). 1999, Vol 155, Num 1, pp 49-58, issn 0014-4886Article

Dystonia induced by combined treatment with L-dopa and MK-801 in parkinsonian monkeysRUPNIAK, N. M. J; BOYCE, S; STEVENTON, M. J et al.Annals of neurology. 1992, Vol 32, Num 1, pp 103-105, issn 0364-5134Article

Comparison of the effects of four cholinomimetic agents on congnition in primates following disruption by scopolamine or by lists of objectsRUPNIAK, N. M. J; STEVENTON, M. J; FIELD, M. J et al.Psychopharmacologia. 1989, Vol 99, Num 2, pp 189-195, issn 0033-3158Article

Chronic treatment with clozapine, unlike haloperidol, does not induce changes in striatal D-2 receptor function in the ratRUPNIAK, N. M. J; HALL, M. D; MANN, S et al.Biochemical pharmacology. 1985, Vol 34, Num 15, pp 2755-2763, issn 0006-2952Article